Pollak R D, Friedlander Y, Pollak A, Idelson M, Blumenfeld A
Department of Medicine, Hadassah University Hospital at Mount Scopus, Jerusalem, Israel.
Genet Test. 2000;4(3):309-11. doi: 10.1089/10906570050501560.
Hyperhomocysteinemia is an independent risk factor for arteriosclerotic vascular disease. It can result from deficiencies of co-factors required for homocysteine metabolism and/or from genetic disorders of its metabolism. The association between the C677T mutation in the methylenetetrahydrofolate reductase (MTHFR) gene and vascular disease is controversial, and may be affected by ethnic origin. A unique feature of the Israeli population is its ethnic diversity. The aim of this study was to study the frequency of the C677T MTHFR mutation in healthy Israeli ethnic groups. The frequency of the mutation was determined in 897 young healthy Jewish and Muslim Arab Israelis of eight different ethnic groups. Marked ethnic differences in the frequency of mutant homozygotes were found, ranging from 2% in Yemenite Jews, 4% in Sephardic Jews, 9% in Oriental Jews, 10% in Muslim Arabs, 16% in North African Jews, and 19% in Ashkenazi Jews. The frequency of mutant homozygotes was significantly higher in Ashkenazi Jews compared to Yemenites Oriental Jews, Sephardic Jews, and Muslim Arabs (chi2 = 12.35p < 0.001, chi2 = 8.17p = 0.004, chi2 = 6.04p = 0.01, chi2 = 6.54 p = 0.01, respectively). Our findings demonstrate the need for matching ethnic background in patients and controls when studying the association between the C677T MTHFR mutation and any disease.
高同型半胱氨酸血症是动脉硬化性血管疾病的一个独立危险因素。它可能源于同型半胱氨酸代谢所需辅助因子的缺乏和/或其代谢的遗传紊乱。亚甲基四氢叶酸还原酶(MTHFR)基因C677T突变与血管疾病之间的关联存在争议,且可能受种族起源影响。以色列人群的一个独特特征是其种族多样性。本研究的目的是研究健康以色列种族群体中C677T MTHFR突变的频率。在897名来自八个不同种族群体的年轻健康犹太和穆斯林阿拉伯裔以色列人中测定了该突变的频率。发现突变纯合子频率存在显著种族差异,从也门犹太人中的2%、西班牙裔犹太人中的4%、东方犹太人中的9%、穆斯林阿拉伯人中的10%、北非犹太人中的16%到阿什肯纳兹犹太人中的19%不等。与也门犹太人、东方犹太人、西班牙裔犹太人和穆斯林阿拉伯人相比,阿什肯纳兹犹太人中突变纯合子的频率显著更高(卡方值分别为12.35,p < 0.001;卡方值为8.17,p = 0.004;卡方值为6.04,p = 0.01;卡方值为6.54,p = 0.01)。我们的研究结果表明,在研究C677T MTHFR突变与任何疾病之间的关联时,患者和对照需要匹配种族背景。